SCHEMBL10247499

SCHEMBL10247499

CCOC(C)n1cc(-c2ncnc3c2ccn3COC(=O)C(C)C)cn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 6/20 0.38
JAK1 P23458 5/20 0.38
TYK2 P29597 3/20 0.38
JAK3 P52333 3/20 0.38
CD274 Q9NZQ7 1/20 0.37
SIGMAR1 Q99720 1/20 0.36
HDAC3 O15379 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC10 Q969S8 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
HDAC9 Q9UKV0 1/20 0.35
HDAC5 Q9UQL6 1/20 0.35
NCOR2 Q9Y618 1/20 0.35
TPH1 P17752 1/20 0.33
MAP3K5 Q99683 3/20 0.33
CYP3A4 P08684 1/20 0.30
ACACB O00763 1/20 0.30
BRD4 O60885 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30749812 0.90 JAK2 (0.37) JAK2JAK1TYK2JAK3CD274
SCHEMBL2605520 0.90 JAK2 (0.37) JAK2JAK1TYK2JAK3CD274
SCHEMBL26541045 0.86 JAK2 (0.42) JAK2JAK1TYK2JAK3CD274
SCHEMBL872289 0.82 JAK2 (0.40) JAK2JAK1TYK2JAK3CD274
SCHEMBL28857054 0.82 JAK2 (0.37) JAK2JAK1TYK2JAK3CD274
SCHEMBL21201787 0.81 JAK2 (0.37) JAK2JAK1TYK2JAK3CD274
SCHEMBL19928581 0.81 JAK2 (0.37) JAK2JAK1TYK2JAK3CD274
SCHEMBL10247590 0.79 SIGMAR1 (0.39) JAK1SIGMAR1TPH1CYP3A4ACACB
SCHEMBL31291526 0.79 JAK2 (0.37) JAK2JAK1TYK2JAK3CD274
SCHEMBL28888596 0.77 JAK2 (0.37) JAK2JAK1TYK2JAK3CD274

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420629-B2 Azetidine and cyclobutane derivatives as JAK inhibitors INCYTE CORPORATION (US) 2013-04-16 US disclosed
US-8420629-B2 Azetidine and cyclobutane derivatives as JAK inhibitors INCYTE CORPORATION (US) 2013-04-16 US disclosed
US-20120077798-A1 AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION 2012-03-29 US disclosed
US-20120077798-A1 AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION 2012-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077798-A1 AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS JAK1, JAK2, JAK3 JAK2 2/4885JAK1 1/4885TYK2 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.